For breast cancer, the combination of three protein markers, oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), has been successfully utilized for clinical decision making and the use of this framework has contributed to the steady decline in the mortality of breast cancer patients. This evidence concerns the gene PGR and breast cancer.